Enhertu (trastuzumab deruxtecan) approved in US
23 December 2019 07:00 GMT Enhertu (trastuzumab deruxtecan) approved in the US for HER2-positive unresectable or metastatic breast cancer following two or more prioranti-HER2 based regimens Accelerated Approval of AstraZeneca and Daiichi Sankyo's Enhertu based on the DESTINY-Breast01 trial that showed clinically meaningful and durable responses AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or